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A B S T R A C T
The conversion of cellular prion protein (PrP) into a misfolded isoform is central to the development of prion
diseases. However, the heterogeneous phenotypes observed in prion disease may be linked with the presence of
other misfolded proteins in the brain. While hyperphosphorylated tau (p.tau) is characteristic of Alzheimer's
disease (AD), p.tau is also observed in human prion diseases. To explore this association in the absence of
potential eﬀects due to aging, drug treatment, agonal stage and postmortem delay we analyzed p.tau and PrP
immunopositivity in mouse models. Analyses were performed on mice inoculated with prion agents, and mice
with PrP amyloid in the absence of prion disease. We observed that p.tau was consistently present in animals
with prion infectivity (models that transmit disease upon serial passage). In contrast, p.tau was very rarely
observed or absent in mice with PrP amyloid plaques in the absence of prion replication. These data indicate that
the formation of p.tau is not linked to deposition of misfolded PrP, but suggest that the interaction between
replication of infectivity and host factors regulate the formation of p.tau and may contribute to the hetero-
geneous phenotype of prion diseases.
1. Introduction
Accumulation of host-encoded protein aggregates in the brain is the
hallmark of a group of neurodegenerative diseases, including
Alzheimer's disease (AD), Parkinson's disease (PD) and prion diseases
[1–4]. Traditionally, the misfolding of speciﬁc proteins has been used to
deﬁne diﬀerent human neurodegenerative diseases. These include
amyloid-β (Aβ) and hyperphosphorylated microtubule-associated-pro-
tein tau (p.tau) in AD; α-synuclein in PD; and misfolded prion protein
(PrP) in prion diseases. Prion diseases diﬀer from other protein mis-
folding diseases due to their infectious aetiology. The infectious agent is
thought to be a misfolded conformer of PrP, which propagates by
binding to and converting normal cellular PrP (PrPC) into the abnormal
aggregated form [5]. Prion agents exist as a number of diﬀerent natural
and laboratory derived strains, which show characteristic diﬀerences in
incubation time and histopathology [6,7]. While the heterogeneous
nature of prion diseases is well recognized, the underling mechanisms
remain poorly understood.
We have shown that PrP amyloid plaques can be formed in mouse
brain in the absence of prion agent replication, suggesting that not all
misfolded PrP is infectious [8]. Thus, proteinopathies similar to AD and
PD can also occur in mice when PrP misfolds [8]. In this manuscript we
will use PrPTSE to refer to accumulation of abnormal PrP in cases with
prion infectivity, and misfolded PrP to denote the formation of ab-
normal PrP in cases that are not transmissible via an infectious me-
chanism. Despite the lack of an infectious aetiology for AD and PD [9],
all of these protein misfolding diseases show some degree of overlap
resulting in a spectrum of disorders with accumulation of more than
one protein in the brain [10]. Therefore, while triggers of disease are
diverse the basic mechanisms driving the formation and spread of
misfolded proteins, and the progression of neurodegeneration may be
similar [11–15].
Deposits of p.tau forming neuroﬁbrillary tangles (NFTs) are char-
acteristic of AD and some human prion diseases with PrP amyloid
plaques in the brain [16]. P.tau is also seen in acquired and familial
prion disease in the form of neuronal and glial inclusions, and as ex-
tracellular dots and rods [10]. In Gerstmann-Strӓussler-Scheinker dis-
ease (GSS), variant Creutzfeldt-Jakob disease (vCJD) and some forms of
sporadic CJD (sCJD), p.tau is mostly seen in the vicinity of amyloid
plaques [17]. P.tau deposition has also been observed in mouse models
of prion disease [18–20]. Despite these observations, analysis of knock-
out [21] and overexpression [22] tau mouse models suggests that tau is
not essential for the development of prion disease. However, it has been
proposed that the formation of toxic Aβ or PrP aggregates leads to the
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formation of p.tau and subsequent aggregation as NFTs or smaller ex-
tracellular aggregates. It is therefore apparent that prion diseases show
a spectrum of tau pathologies, and that these may be linked with its
heterogeneity. We therefore aimed to assess the correlation between
p.tau and PrP aggregation in models of infectious murine prion disease
and non-infectious PrP proteinopathy. This will determine whether
prion infection/agent replication or misfolded PrP accumulation are
important in determining disease phenotype.
2. Materials and methods
2.1. Animal models
All tissues examined in this project were produced in previous
transmission experiments [23–25] performed under licence from the
UK Home Oﬃce in accordance with the Animals (Scientiﬁc Procedures)
Act 1986. Archive blocks were re-cut to produce sections for analysis of
p.tau, PrP and amyloid accumulation. Frozen tissue from the mouse
models used in these studies was not available for biochemical analysis.
The severe tauopathy seen in squirrel monkeys infected with clas-
sical bovine spongiform encephalopathy agent (SQ-BSE) [26] led us to
analyze the phenotype associated with disease in knock-in transgenic
mice expressing bovine PrP with the 6-octapeptide repeat region (Bov6)
[27] inoculated intracerebrally with classical BSE (C.BSE), H-type
(H.BSE) and bovine amyloidogenic spongiform encephalopathy (BASE)
[24]. To explore the correlation between PrP amyloid and p.tau we
used the following models: (i) Wt mice injected with 87V murine
adapted scrapie (87V-VM) [28]; (ii) transgenic mice that overexpress
mutant PrP-101L (GSS-22) [29] and (iii) 101LL mice inoculated with
recombinant wild-type PrP (rec.Wt-PrP) and recombinant mutant PrP
(rec.PrP-101L) ﬁbrils [8,30]. To study p.tau accumulation in animals
with large amounts of widespread non-amyloid (diﬀuse) PrPTSE de-
posits we used C57-BL mice inoculated with ME7 murine adapted prion
agent (ME7-C57BL) [25,31]. Four animals per group were analyzed
after developing clinical disease or at the end of their expected lifespan.
Non-inoculated Bov6, C57BL, VM, 101LL and 129Ola mice served as
controls.
2.2. Neuropathology
Formalin ﬁxed, paraﬃn embedded brain sections (6 μm) were
processed and stained using published protocols [26]. For light mi-
croscopy sections were stained with haematoxylin-eosin (HE) and im-
munostained for the detection of PrP with monoclonal antibody 6H4 at
5 μg/ml (Celtic diagnostics 01–010) that recognizes residues 144–152
of mouse PrP [32]. Hyperphosphorylated tau was detected with anti-
bodies AT8 at 4 μg/ml (Thermo MN1010) and Thr231 (AT180) at
0.05 μg/ml (Thermo MN1040). Antibody AT8 recognizes a triple
phosphorylated peptide (pS202, pT205 and pS208) present in AD pa-
tients [33] which has been used for detection of p.tau in humans and
animals [34]. Results obtained with AT8 suggest a correlation between
p.tau and neurodegeneration [35–37]. Antibody Thr231 has been used
in humans, natural diseases in animals and in experimental models
[38,39]. Both antibodies recognize the proline-rich domain of tau that
is important for microtubule binding and assembly [40]. Sections were
incubated in the appropriate primary antibody, followed by incubation
in the appropriate biotinylated secondary antibody and developed
using ABC Elite Kit (Vector Labs).
Amyloid deposits were detected in thioﬂavin-s treated sections [41].
In all models we analyzed two areas of the cerebral cortex (cingulate
and retrosplenial), septum, hippocampus, thalamus, hypothalamus,
colliculus, cerebellum and brainstem. Three observers performed the
neuropathologic characterization of p.tau and PrP TSE deposition. Tissue
sections were scored for intensity and type of p.tau and PrP deposition
in nine regions of the brain in the eight models used here using a four
point scale of 0 (absent) to 3 (severe) previously described. Lesion
proﬁling has been used extensively to identify neuropathologic phe-
notypes in humans and animals with neurodegeneration [24,42–44].
The analysis was carried out independently by three observers blinded
to the experimental design.
2.3. Double labelling of PrP and tau
Double immunoﬂuorescent labelling of PrP and tau was performed
using 1B3 rabbit polyclonal PrP antibody and AT8 antibody. Sections
were incubated in 1B3 [45] at 10 μg/ml and AT8 at 4 μg/ml (antibody
mixture) and incubated overnight at room temperature. Secondary
antibodies, goat anti rabbit Alexa ﬂuor 488 and donkey anti mouse
Alexa ﬂuor 594 (Thermo) (20 μg/ml) were incubated for 1 h at room
temperature, sections were washed in water and mounted using ﬂuor-
escent mounting media (Dako S3023).
2.4. Laser scanning confocal microscopy and reconstruction of 3D images
Confocal detection of PrP and p.tau immunopositivity were ob-
tained on a Zeiss LSM710 laser scanning microscope (×63) oil im-
mersion objective. Images (1024 × 1024 pixels) were obtained and
serial optical sections taken at intervals of 1 μm in the Z dimension.
Multitrack sequential acquisition settings were used to avoid inter-
channel cross-talk. Excitation was via a 594 nm diode-pumped solid-
state laser and the 488 nm line of an argon ion laser. Imaris software
version 6.4.2 (Bitplane, South Windsor, CT), was used to analyze the
correlation between PrP and tau. “Surface” tool was utilised to build a
computer-generated representation of the confocal image. Brieﬂy, in
“Surpass mode” “Create surface” option was selected for the channel of
interest then “smoothing” option was disabled and “background sub-
traction” was enabled. Switching to “Slice mode” allowed for accurate
measurements to be obtained for background correction. “Voxel
threshold” graph was altered to map the PrP/tau signal with precision
and “ﬁnished surface creation” was selected. Images of reconstructed
data-sets were saved accordingly.
3. Results
3.1. P.tau and PrPTSE in typical and atypical BSE infected Bov6 mice
Hyperphosphorylated tau has been described in experimental
models following transmission of C-BSE agent [18]. However, no in-
formation is available in transmission experiments using atypical BSE
agents. Here, we used Bov6 mice inoculated with C.BSE, H.BSE and
BASE and observed widespread p.tau immunopositivity forming dots
and rods in multiple areas of the brain, including cerebral cortex,
septum, hippocampus, thalamus, hypothalamus, colliculus and brain-
stem (Table 1). Similar patterns and distribution of immunoreactivity
were observed in adjacent sections stained with antibodies AT8 and
Thr231. Abundant deposits and strong reactivity was consistently seen
with antibody AT8 in Bov6 inoculated with BASE (Table 1). Tau im-
munopositivity was identical to that described in SQ-BSE [26], in some
human prion diseases [17,46] and primary tauopathies [47]. The tha-
lamus of Bov6 mice inoculated with C.BSE showed larger amounts of
PrPTSE than the thalamus of Bov6 mice inoculated with BASE or H.BSE
(Fig. 1a–c) (Table 2). However, p.tau positivity was most prominent in
the thalamus of BASE infected mice (Fig. 1e) (Table 1). In contrast, the
superior colliculus of Bov6 mice exposed to BASE (with severe spon-
giform degeneration) showed prominent accumulation of both PrPTSE
(Fig. 1h) and p.tau (Fig. 1k) (Tables 1 and 2). Bov6 mice inoculated
with H.BSE accumulated the smallest amounts of both PrPTSE and p.tau
(Fig. 1c,f,i,l). The absence of thioﬂavin-s ﬂuorescent plaques in the
colliculus indicates that p.tau is not associated with PrP-amyloid in this
brain area. However, PrPTSE amyloid and p.tau were seen in the tha-
lamus and brainstem. Confocal images of isolated immunopositive de-
posits (Fig. 2a–c) show co-localization between PrPTSE and p.tau. In
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addition, p.tau is also observed in the vicinity of the PrPTSE central core.
Imaris 3D reconstruction (Fig. 2d–f) conﬁrm the previous observation
and revealed p.tau deposition throughout the PrP plaque in C-BSE and
H-BSE (Fig. 2d–f). No immunoreactivity was observed in brain sections
of non-inoculated aged matched Bov6 probed with antibodies AT8 or
Thr231 or in BSE infected Bov6 mice incubated without primary anti-
body. Therefore, widespread accumulation of p.tau is present in the
brain of Bov.6 mice infected with typical and atypical BSE agents.
Table 1
Scoring of p.tau deposition in experimental mouse models.
Med Cer Coll Hypo Thal Hippo Sep Cin.Cx Ret.Cx
Bov6-H.BSE ++ − + + + ++ +++ +++ +++
Bov6-C.BSE +++ +/− + ++ ++ + +++ ++ ++
Bov6-BASE +++ − +++ +++ +++ ++ + +++ ++
87V-VM + − − ++ + + + +++ +++
ME7-C57BL +/− − + + + + + + +
GSS-22 +/− − − − − − − − −
101LL-rec.Wt-PrP − − − − − − − − −
101LL-rec.PrP-101L − − − − − − − − −
Tau deposition scored as the following (−) no deposition; (+) low deposition; (++) moderate deposition; (+++) heavy deposition, results based on mean of 4 mice per group. Med-
medulla, Cer-cerebellum, Coll-colliculus, Hypo-hypothalamus, Thal-thalamus, Hippo-hippocampus, Sep-septum, Cin.Cx-cingulate cortex, Ret.Cx-retrosplenial cortex.
C.BSE/Bov6 BASE/Bov6 H.BSE/Bov6
6H4/PrP
AT8/tau
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Fig. 1. PrPTSE and p.tau in Bov6 mice challenged with typical and atypical BSE.
Large, moderate and low amounts of PrPTSE were observed in the thalamus of Bov6 mice inoculated with C.BSE, BASE and H.BSE respectively (a–c). Large amounts of p.tau im-
munopositivity were observed in Bov6 mice inoculated with BASE (e) and lower amounts of p.tau were observed in Bov6 mice inoculated with C.BSE (d) and H.BSE agents (f). Large
amounts of PrPTSE (h) and p.tau (k) were observed in the superior colliculus of Bov6 mice inoculated with BASE; lower amounts of both PrPTSE and p.tau were observed in Bov6 mice
inoculated with C.BSE (g, j) and H.BSE (i, l). Images obtained after staining with anti-PrP antibody 6H4 (a–c, g–i), anti-p.tau antibody AT8 (d–f, j–l) and counterstained with haema-
toxylin. Scale bar in f = 100 μm (corresponding to panels a–f). Scale bar in l = 50 μm (corresponding to panels g–l).
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3.2. P.tau in mice inoculated with diﬀerent scrapie strains
ME7-C57BL and 87V-VM are well characterized mouse passaged
scrapie strains with diﬀerent time courses of disease (160 days/ME7-
C57BL, 320 days/87V-VM) and pathologic phenotypes. ME7-C57BL
infected mice show large amounts of widespread, diﬀuse (i.e. non-
amyloid) PrPTSE accumulation and few plaques (Fig. 3a,b and Table 2),
with severe astro- and micro-gliosis in all areas of the brain [25,31]. In
contrast, 87V-VM infected mice show widespread unicentric amyloid
plaques, and coarse and ﬁne-punctate PrPTSE deposits in the brain
(Fig. 3e,f and Table 2). 87V-VM mice also show selective targeting of
the CA2 region of the hippocampus with spongiform degeneration and
ﬁne-punctate PrPTSE[25,48]. ME7-C57BL mice (160 dpi) show limited
amounts of p.tau in most areas of the brain at terminal disease
(Table 1). This pattern of p.tau accumulation was seen in regions with
spongiform degeneration and PrPTSE accumulation (Fig. 3c,d). In 87V-
VM infected mice, p.tau was observed within and around PrPTSE amy-
loid plaques at terminal disease (320 dpi) (Fig. 3h). P.tau was also
observed in regions with diﬀuse PrPTSE deposits (Fig. 3g) Table 1.
Confocal and Imaris 3D reconstruction of double labeled sections show
p.tau colocalised with PrPTSE aggregates throughout the plaque in 87V/
VM and ME7/C57 models (Fig. 4a–d). The spatial proximity between
p.tau and PrPTSE suggest an association between interacting structures
(Fig. 4c,d). In conclusion, transmission of mouse adapted scrapie strains
elicit the widespread formation of p.tau in multiple brain areas, with
87V/VM strain inducing the largest amount of p.tau in the cerebral
cortex in areas with PrP-amyloid.
3.3. Dissociation between misfolded PrP and p.tau in mice overexpressing
PrP P101L
GSS-22 mice overexpressing PrP-P101L spontaneously develop se-
vere spongiform degeneration, abundant PrP amyloid plaques and
gliosis in the brain, but do not replicate prion infectivity and do not
transmit prion disease to Wt or 101 LL mice [23,29]. Therefore, GSS-22
provide a model to study the possible correlation between PrP ag-
gregates and p.tau in animals that express mutant PrP throughout their
lifespan but are not exposed to the trauma of intracerebral inoculation,
Table 2
Scoring of PrP deposition in experimental mouse models.
Med Cer Coll Hypo Thal Hippo Sep Cin.Cx Ret.Cx
Bov6-H.BSE +/++ − − + + +/− + + +
Bov6-C.BSE ++ + + + +++ ++ +++ + ++
Bov6-BASE +++ +/++ +++ + ++ +/++ − + +/++
87V-VM + +/− +/− ++ +++ ++ + ++/+++ ++/+++
ME7-C57BL +++ +++ +++ +++ +++ +++ +++ +++ +++
GSS-22 ++ +/− − +/− +/− ++/+++ + ++ +++
101LL-rec.Wt-PrP − − − − − +++ − − −
101LL-rec.PrP-101L − − − − − +++ − − −
PrP deposition scored as the following (−) no deposition; (+) low deposition; (++) moderate deposition; (+++) heavy deposition, results based on mean of 4 mice per group. Med-
medulla, Cer-cerebellum, Coll-colliculus, Hypo-hypothalamus, Thal-thalamus, Hippo-hippocampus, Sep-septum, Cin.Cx-cingulate cortex, Ret.Cx-retrosplenial cortex.
C.BSE BASE H.BSE
a b c
d e f
Fig. 2. Association of PrPTSE and p.tau in Bov6 mice challenged with typical and atypical BSE.
Double ﬂuorescent labelling allows for detailed confocal analysis of PrPTSE and p.tau interactions. Confocal analysis of plaque like PrPTSE (red) and p.tau (green) in the thalamus of Bov.6
mice inoculated with C.BSE (a), BASE (b) and H.BSE (c). 3D Imaris rendering of confocal z-stacks reveals p.tau deposition is closely associated with plaque like PrPTSE deposition in C.BSE
(d), BASE (e) and H.BSE (f). Images obtained after double labelling with anti-PrP antibody 1B3 and anti-p.tau antibody AT8 and Alexa 488 and 594 ﬂuorescent secondary antibodies.
Scale bars in a–c = 10 μm, Scale bars in d–f = 5 μm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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or develop a transmissible disease [23,29]. We observed that despite
the severe spongiform degeneration (Fig. 5d) and large accumulation of
PrP plaques in the brain (Fig. 5b,e and g), these animals show almost
complete absence of p.tau in all brain areas at terminal disease (Tables
1 and 2). This unexpected ﬁnding was conﬁrmed by confocal micro-
scopy (Fig. 5h). Similar results were obtained in sections probed with
both antibodies AT8 and Thr231. Therefore, we observed a striking
dissociation between severe spongiform degeneration and abundant
PrP amyloid formation, and deposition of p.tau.
3.4. No p.tau is seen in 101LL mice following seeding of PrP amyloid
plaques
We recently described a model of seeded PrP proteinopathy fol-
lowing the inoculation of rec.Wt-PrP and rec.101L-PrP amyloid ﬁbrils
into knock-in mice homozygous for the proline to leucine mutation at
PrP codon 101 (101LL) [8]. Inoculated 101LL mice did not develop
clinical signs of prion disease, spongiform degeneration of the brain, or
replication of infectious prions, but accumulated large PrP amyloid
plaques in the area of inoculation and vicinity (i.e., the corpus callosum
and hippocampus) [8]. This model could support the analysis of the
correlation between misfolded PrP and p.tau without potential artifacts
due to overexpression of PrP, or pathogenic mechanisms associated
with prion agent replication and the formation of spongiform en-
cephalopathy. In addition, inoculation of recombinant PrP ﬁbrils allows
analysis of p.tau formation in the absence of other components present
in brain extracts that could enhance or inhibit the formation of p.tau
isoforms. Although multiple PrP amyloid plaques were observed in the
hippocampus and the corpus collosum of 101LL mice inoculated with
Wt-rec or 101L-rec PrP ﬁbrils (Fig. 6a, b), immunolabelling with anti-
bodies AT8 and Thr.231 showed no p.tau in any area of the brain in
both models (Fig. 6c, d). Thus, despite the co-localization of p.tau with
PrPTSE amyloid plaques in 87V-VM scrapie, and association with pla-
ques described in other studies [19,49,50] results obtained in GSS-22
mice (overexpressor) and 101LL mice inoculated with recombinant PrP
ﬁbrils show that PrP-amyloidogenesis is not invariably associated with
the formation of p.tau isoforms (Table 3).
brainstem
e g
cingulate
cortex 
hf
6H4/PrP AT8/tau
CA3
septum
a c
b d
M
E7
/C
57
BL
87
V
/V
M
M
E7
/C
57
BL
87
V
/V
M
Fig. 3. PrPTSE and p.tau deposition in the 87 V/VM and
ME7/C57BL scrapie mouse models.
In the ME7/C57BL model ﬁne punctate and coarse PrPTSE
deposits were observed in the CA3 region of the hippo-
campus (a) and in the septum (b). Minimal p.tau positivity
was observed in the CA3 region of the hippocampus (c) and
septum (d). Labelling in septum showed plaque like PrP
deposition. In the 87V/VM model plaque-like, ﬁne punc-
tate and coarse immunopositive PrPTSE deposits were ob-
served in the brainstem (e) and cingulate cortex (f). P.tau
immunopositivity in the cingulate cortex (h) appeared to
be located around and inside PrP plaques. Minimal punc-
tate p.tau deposits were observed in the brainstem (g).
Images obtained after staining with anti-PrP antibody 6H4
(a, b, e, f), anti-p.tau antibody AT8 (c, d, g, h) and coun-
terstained with haematoxylin. Scale bar in d = 50 μm
(corresponding to panels a–d). Scale bar in g = 50 μm
(corresponding to panels (e–h).
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4. Discussion
Aggregates of tau protein are observed in several neurodegenerative
diseases, and are thought to be responsible for neurotoxicity and cell
death [51,52]. Studies in mice showed that expression of human tau
protein is not essential for the formation of Aβ plaques, but that it is
necessary for neurotoxicity [53,54]. The role of p.tau in prion disease is
unknown. A recent study stated that the frequency of tau pathology is
not unusually high in sCJD (the most common prion disease in humans)
and that it does not relate to PrPTSE deposition [10]. However, the
spectrum of tau pathologies in prion diseases suggest that p.tau could
be a factor in the heterogenous presentation of these disorders. To study
whether p.tau deposition was associated with prion replication and
neurodegeneration, or occurred as a result of PrP misfolding and ag-
gregation we analyzed mouse models with (i) accumulation of PrPTSE
either in the form of diﬀuse deposits or amyloid plaques that are
transmissible via an infectious mechanism as shown by serial passage;
and (ii) non-infectious PrP proteinopathy, in which PrP amyloid pla-
ques are seeded in the absence of agent replication.
Previous studies showed p.tau in animals inoculated with C-BSE
[18]. Whether experimental animals exposed to atypical BSE (i.e., BASE
or H-BSE) develop similar phenotype is unknown. Here, we observed
that Bov6 mice infected with typical and atypical BSE agents showed
widespread accumulation of p.tau in brain areas with spongiform de-
generation, gliosis and PrPTSE at terminal disease. The largest amounts
of p.tau were seen in mice inoculated with BASE. P.tau has recently
been described in bovines with Idiopathic Brainstem Neuronal Chro-
matolysis (IBNC) showing that tau pathology might be a widespread
phenomenon in the animal kingdom [55]. In mice infected with rodent-
adapted prion strains, p.tau deposition varied depending on PrPTSE
deposition type. In ME7-C57BL p.tau was detected mainly in areas with
diﬀuse PrPTSE and spongiform degeneration. However in 87 V infected
mice, p.tau was mainly associated with PrP amyloid plaques but was
also seen in areas with spongiform degeneration and non-amyloid
PrPTSE deposition. The molecular mechanisms underlying p.tau accu-
mulation remain poorly understood. Previous studies have shown that
the N-terminus (amino acids 1–19) and tandem repeats region (amino
acids 186–283) of tau protein interact with PrP. In addition, the octa-
peptide repeat region of PrP is involved in the binding activity of PrP
with tau [56]. The reported molecular interactions between tau and PrP
highlight the potential role of tau in PrP function and its possible in-
volvement in the pathogenesis of prion diseases.
GSS-22 mice overexpressing PrP 101L [29] and 101LL mice in-
oculated with recombinant PrP amyloid ﬁbrils [8] represented animal
models without infectious prion disease, but which formed PrP amyloid
plaques in the brain. In contrast to the plaque associated p.tau staining
observed in 87V infected mice, p.tau deposits were exceptionally rare in
GSS22 mice, and completely absent from 101LL mice inoculated one
possibility is that PrP amyloid might not induce p.tau recognized by
antibodies AT8 and Thr231. This possibility is unlikely because these
antibodies are extensively used for the detection of abnormal tau in
humans and animals. Another possibility is that GSS22 animals did not
live long enough (180 days) to accumulate readily detectable p.tau by
immunohistochemistry. However, p.tau was present in multiple brain
areas of ME7/C57 mice at 160 dpi suggesting that its accumulation is
not a phenotypic trait in GSS 22 mice. Importantly, 101LL mice in-
oculated with rec-PrP ﬁbrils with large PrP-amyloid plaques show
complete absence of clinical disease and p.tau up to 500 dpi. Therefore,
87V/VM ME7/C57BL
a b
c d
PrP
tau
PrP
tau
Fig. 4. Association of PrPTSE and p.tau in the 87 V/VM and
ME7/C57BL scrapie mouse models.
Confocal analysis of plaque like PrPTSE (red) and p.tau
(green) in the cortex of 87V infected VM mice (a) and in
the septum of ME7 infected C57BL mice (b). 3D-Imaris
rendering revealing close association and interaction of
PrPTSE and p.tau (c,d). Images obtained after double la-
belling with anti-PrP antibody 1B3 and anti-p.tau antibody
AT8 and Alexa 488 and 594 ﬂuorescent secondary anti-
bodies. Scale bar = 5 μm (a and c), scale bar 10 μm (b)
corresponding to panels b and d. (For interpretation of the
references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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GSS-22 and 101LL rec-PrP mouse models show dissociation between
misfolded PrP and p.tau. Future studies should be geared towards un-
derstanding why a misfolded protein has the potential to aggregate and
lead to the development of a complex proteinopathy that can be
transmitted between hosts posing a risk to public health. In conclusion,
our studies indicate that p.tau is a phenotypic feature of prion diseases
and might be a factor in the heterogenous spectrum of these disorders.
The data presented here suggest that replication of prions, or prion
induced neurotoxicity rather than the physical conformation of PrP is
crucial for the abnormal processing of tau.
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Fig. 5. Abundant PrP with minimal p.tau accumulation in
GSS-22 mice.
Severe spongiform encephalopathy (a, d) and numerous
plaques, (arrows in d) in the cerebral cortex of GSS-22
mice overexpressing PrP 101L. Numerous PrP deposits in
the cerebral cortex (b, e, g) and hippocampus of GSS-22
mice (b). Minimal p.tau positivity in the cortex (c, f, and h
(arrow)). Light microscopy images obtained after staining
with haematoxylin and eosin (a, d), anti-PrP antibody 6H4
(b, e) and anti-p.tau antibody AT8 (c, f) and counterstained
with haematoxylin. Confocal images obtained after double
labelling with anti-PrP antibody 1B3 and anti-p.tau anti-
body AT8 and Alexa 488 and 594 ﬂuorescent secondary
antibodies. Scale bar = 500 μm (a–c); scale bar = 100 μm
(d–f), scale bar = 20 μm (g), scale bar = 10 μm (h).
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